Sangamo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
09/05/2024 22:22
* Sangamo Therapeutics Inc SGMO.OQ reported a quarterly
adjusted
loss of 27 cents per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of 12 cents. The mean expectation of eight analysts for the
quarter was for a loss of 21 cents per share. Wall Street
expected results to range from -27 cents to -10 cents per share.
* Revenue fell 99.7% to $481.00 thousand from a year ago;
analysts
expected $6.65 million.
* Sangamo Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents.
* The company reported a quarterly loss of $49.09 million.
* Sangamo Therapeutics Inc shares had fallen by 25.0% this
quarter and lost 7.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 97.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $2.50
This summary was machine generated from LSEG data May 9 at 09:22
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.21 -0.27 Missed
Dec. 31 2023 -0.26 -0.34 Missed
Sep. 30 2023 -0.32 -0.59 Missed
Jun. 30 2023 -0.34 -0.66 Missed